A mechanism-based classification of pain in multiple sclerosis
Abstract Pharmacological treatment of pain in multiple sclerosis (MS) is challenging due to the many underlying pathophysiological mechanisms. Few controlled…
central neuropathic pain
Prescribing cannabis for harm reduction
Abstract Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may…
Recent data on cannabinoids and their pharmacological implications in neuropathic pain
Abstract Natural cannabinoids have been used for centuries for their psychotropic properties, but their possible therapeutic implications in analgesia have…